Press Release 2008

User Rating: 0 / 5

Star InactiveStar InactiveStar InactiveStar InactiveStar Inactive
 

PISCATAWAY, N.J., Aug. 18, 2008 – A recent University of Texas – MD Anderson Cancer Center study was published in the peer review American Association for Cancer Research’s journal Clinical Cancer Research 14.14 (July 2008). Results of an eight-week human, phase II trial of the patented ingredient Curcumin C3 Complex® by Sabinsa, indicated orally-ingested curcumin is well-tolerated in pancreatic cancer patients and, despite limited absorption, curcuminoids showed biological efficacy in some patients with pancreatic cancer.

Titled “Phase II Trial of Curcumin in Patients with Advanced Pancreatic Cancer,” the peer-reviewed paper derives from a study that administered 8 grams of orally-ingested C3 Complex (as determined safe in phase I trials) daily to 25 patients, with thorough evaluation of disease progression over the two-month period. Markers for disease progression — notably inflammatory transcription factor nuclear factor-kappa B (NF-kappa B) and pro-inflammatory cyclooxygenase-2 (Cox-2) enzyme levels — were monitored in the 21 patients deemed reportable for treatment response. Results indicated that C3 Complex significantly lowered expression of disease biomarkers NF-kappa B and Cox-2. Two patients showed clinical biological activity. One had ongoing stable disease for over 18 months, and the other one had a brief, but marked, tumor regression (73% regression) accompanied by changed pattern in serum cytokines. No subjective or objective side effects were observed in the study.

“Pancreatic cancer remains one of the most fatal and short-prognosis cancers, with few available treatments for the disease, and virtually no overwhelmingly positive-result treatment,” said Vladimir Badmaev, M.D., Ph.D., Sabinsa Corporation vice president of scientific and medical affairs and paper co-author. “Therefore, there is an urgent search for more effective and safe therapies. This study’s experimental evidence indicates that increased expression of NF-kappa B contributes to rapid progression of pancreatic cancer, and that curcumin and its derivatives can suppresses NF-kappa B activation and slow down or inhibit progression of the cancer in some patients, despite limited absorption of curcumin.”

For an electronic copy of the discussed paper, please contact Clint Curry at This email address is being protected from spambots. You need JavaScript enabled to view it..

Sabinsa’s Curcumin C3 Complex® is an extract of turmeric roots standardized for 95 percent of phenolic compounds called curcuminoids. The same ground, dried roots of turmeric, which have been used for centuries as a spice (curry), food preservative and a coloring agent, have been found to be a rich source of phenolic compounds (curcuminoids) with versatile biological mechanisms. In the last three years alone there have been several pioneering IND (Investigational New Drug) studies granted by the FDA and other NIH funded studies for the investigation of C3 Complex in the treatment of patients with cancer, neurodegenerative diseases and diseases characterized by chronic inflammatory process.

    HEADQUARTERS

  • Sabinsa Corporation
    20 Lake Drive
    East Windsor
    NJ 08520, USA

  • +1 732 777 1111
  • +1 732 777 1443
  • info@sabinsa.com

CERTIFICATES

Certificate Logos Certificate Logos Certificate Logos Certificate Logos

CONTACT US